NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung ...
Therapeutics and collaborators at The University of Texas MD Anderson Cancer Center presented late-breaking results from a Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback